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A PILOT STUDY: OBSERVATIONS OF PATIENTS PARTICIPATING IN HEART 









 The purpose of this pilot project was to examine descriptive statistics from 
patients who participated in heart failure (HF) shared medical appointments (SMAs) at a 
mid-sized heart center in the Northwest, in which nutrition education was provided by 
an RD. Information collected included blood pressure (BP), heart rate (HR), weight, 
scores from the Minnesota Living with Heart Failure (MLHF) Survey, and the Atlanta 
Heart Failure Knowledge (AHFK) questionnaire. Due to small sample size and lack of 
control group, simple descriptive statistics, such as mean and median were used to 
examine the data. Three of the participants were female and 4 were male. Five patients 
in this group had a diagnosis of HF with reduced ejection fraction (HFrEF), and two 
patients had a diagnosis of HF with preserved ejection fraction (HFpEF). Average weights 
of the participants ranged from 171.4 lbs to 339.6lbs. Quality of life (QOL) for this group 
of patients was diverse, average MLHF scores ranging from 0.4-78.3. The 3 lowest scores 
on the MLHF questionnaire and the 3 lowest average HRs were observed in the 3 
patients (21, 22 & 32) who had the lowest recorded weights in the group (<200lbs). The 
iv 
 
2 highest average BPs were observed in the 2 patients (20 & 25) with HFpEF. One limited 
potential trend that was detected within this data was that the 3 patients with average 
weights <200lbs appeared to have lower MLHF scores (indicating higher QOL), as well as 
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A PILOT STUDY: OBSERVATIONS OF PATIENTS PARTICIPATING IN HEART 




 Heart Failure (HF) contributes about $30.7 billion to healthcare costs annually, 
and impacts approximately 5.7 million Americans (Centers for Disease Control and 
Prevention [CDC], 2019). HF is a type of heart disease, which falls under the umbrella 
term: cardiovascular disease (CVD), which includes any disease or condition impacting 
the cardiovascular system (“What is Heart Failure,” 2017). The heart is the driving force 
of the circulatory system, and is responsible for pumping blood sufficiently to support the 
rest of the body (Heart Failure, n.d). When its ability is restricted, it can result in HF 
(“What is Heart Failure,” 2017). HF can be divided into 3 types: left sided HF, right sided 
HF, and congestive HF (CHF), often referred to as just HF. Once a HF diagnosis is made, 
the severity of HF (class I - class IV) is determined, based on the symptoms that an 
individual displays, as well lab tests/imaging (“Classes of Heart Failure”, n.d). Risk 
factors that can contribute to the development of HF include: coronary artery disease 
(CAD), high blood pressure/hypertension (HTN), diabetes (DM), smoking, a high 
sodium, high cholesterol, and high saturated fat diet, lack of physical activity, as well as 
obesity (CDC, 2019).  
 Treatment for HF includes a combination of medical and lifestyle approaches. 
Medications are used to help control underlying diseases, such as HTN, CAD, and DM, 
to decrease overall stress on the heart. Lifestyle changes, such as increasing physical 
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activity and changing dietary patterns, are also recommended. The 2015-2020 Dietary 
Guidelines recommend that a person consuming a 2,000 calorie diet should have: 2 ½ 
cups of vegetables, 2 cups of fruits, 6oz of grains (half of which are whole grain), 3 cups 
of low fat or fat free dairy, 5 ½ oz. protein, 5 tsp of non-tropical oils, and sugar and 
saturated fats should be limited (A Closer Look Inside, n.d). The American Heart 
Association (AHA) also emphasizes those same foods, as well as incorporating nuts and 
legumes, reducing added sugars, and limiting sodium consumption to 1,500-
2,300mg/day. The AHA recommends the DASH (Dietary Approaches to Stop 
Hypertension) diet as a suitable diet for Americans to follow, as it includes all of the 
recommended components (The American Heart Association Diet and Lifestyle 
Recommendations, 2017). 
  In 2016, the American Heart Association reported that, despite survival rates 
increasing, about half of those diagnosed with HF will not live past 5 years (Mozaffarian 
et al., 2016). Therefore, it is evident that additional interventions should be assessed 
regarding the maintenance of this disease. One proposed method is through shared 
medical appointments (SMAs). An SMA is typically a small group of approximately 10-
15 patients, all with the same or related medical diagnosis/condition. These patients are 
seen by a multi-disciplinary medical team consisting of a nurse, a doctor, a pharmacist, 
and sometimes a dietitian. Together the patients share their experiences, concerns, 
questions, and discuss past stories with the SMA group (Shared Medical Appointments, 
n.d). SMAs are considered to be most beneficial for patients with chronic conditions, 
such as diabetes, HTN, asthma and heart disease/ HF (Shared Medical Appointments, 
n.d). In their 2016 article, Smith et al. found that a group of 92 patients involved in a HF 
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SMA rated the appointments highly and reported that the discussions and sharing stories 
and points of view was one of the most beneficial ways to help with the management of 
HF. Additionally, it was found that there was a decrease of 33% in re-hospitalizations due 
to HF compared to the control group (Smith, 2015). Shared medical appointments are a 
newer concept for the maintenance of chronic health conditions, and while there is 
research supporting the use SMAs, there is limited research available regarding the 
potential benefits of adding a Registered Dietitian (RD) to the SMA team. When 
considering the research regarding SMAs and nutrition education, there are a few gaps in 
the literature that future research can shed some light on. The mode that nutrition 
education is provided, either by an RD or other healthcare provider, is one gap that has 
not been extensively studied. Further research is warranted to determine if RD provided 
nutrition education might provide additional benefits to patients. Another area for further 
research is the influence of the consistency and duration of nutrition education provided. 
 In a 2014 study, Smith et al. followed an intervention and a control group for 1 
year. The SMA group received self-management education, which covered a variety of 
topics, for 4 weeks, and then once more at the 6 month mark. For the standard care group, 
the participants received education after discharge, a phone call, and then one more 
follow up within 1 month. Some promising results were observed, such as the SMAC-HF 
(Self- Management & Care of Heart Failure) group rated the meetings very positively. 
However, the researchers also noted that more research is needed regarding the benefits 
of “additional booster sessions,” or consistency of education provided over a 12-month 
period of time (Smith et al., 2014). In 2016, Smith et al., reported outcomes after 72 
appointments between the intervention group and the control group, finding similar 
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results as the 2014 study. They also found decreases in hospitalizations in the group 
clinic patients group versus the group that received standard care (Smith et al., 2015). 
While this study looked at the effects of consistent education over a 12 month period, the 
education was varied, and did not provide extensive nutrition education, beyond 
following a low sodium diet, managing fluids, and providing a recipe book (Smith et al., 
2015).  
 As the number of HF diagnoses continues to rise, and dietary intake remains one 
of the main lifestyle focuses for controlling risk factors (cholesterol, HTN, type two 
diabetes, CAD) that impact HF outcomes, it is important that extensive nutrition 
education is incorporated into group medical appointments. Therefore, the purpose of this 
pilot project is to collect and report descriptive statistics from participants who 

















Anatomy/ how heart works                  
 In order to better understand the etiology, diagnosis, treatment and prevention of 
HF, the anatomy and physiology of the heart must first be discussed. The circulatory 
system consists of the heart, the arteries, the capillaries, the veins, the blood vessels, and 
the blood (“How the Heart Works,” n.d.). The driving force of the circulatory system is 
the heart, which is made up of 4 chambers. Within those chambers lies the right and left 
atriums, the pulmonary, aortic, tricuspid, and the mitral valves, along with the right and 
left ventricles. The main function of the heart is to pump blood throughout the body, 
delivering nutrients and oxygen to the organs. The heart is connected to the circulatory 
system by association to veins and to arteries (“How the Heart Works,” n.d.) and the 
direction of blood flow is managed by the opening and closing of valves (“How the 
Healthy Heart Works, n.d). De-oxygenated blood flows from the body to the heart’s right 
atrium, and from the right atrium, it travels down to the right ventricle, by the opening of 
the tricuspid valve (“How the Healthy Heart Works, n.d).When the pulmonary valve 
opens, blood travels from the right ventricle to the pulmonary artery, where it can be sent 
to the lungs for oxygenation. After oxygenation, blood travels back to the heart’s left 
atrium via the pulmonary veins. The blood is sent to the left ventricle via the mitral valve, 
and from there the blood can be sent to the aorta and back into circulation (“How the 
Healthy Heart Works, n.d).The flow of blood through the heart (the cardiac cycle) can be 
divided into 2 categories, systole and diastole (Fukuta & Little, 2009). Systole occurs 
when the heart contracts and ejects, and diastole occurs when the heart goes through 
“isovolumetric relaxation, early diastolic filling, diastasis, and atrial filling” (Fukuta & 
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Little, 2009). In an individual with no heart complications, the heart is able to fill, empty 
and contract adequately (Fukuta & Little, 2009), and is strong enough to pump blood at a 
sufficient rate to support the body (“How the Heart Works,” n.d). HF occurs, not when 
the heart ceases to pump blood, but when the ventricles of the heart are unable to pump 
enough blood to maintain the function of the body’s organs (Nelms, 2011, p. 326).  
Heart Failure & Diagnosis 
 Heart Failure, along with myocardial infarction, dilated cardiomyopathy, mitral 
valve regurgitation and prolapse, and congenital heart failure, is a type of heart disease, 
which falls under the overarching term: cardiovascular disease (Felman, 2020). HF 
occurs when the heart becomes weak and is not able to pump sufficient amounts of blood, 
containing oxygen and nutrients, to support and sustain proper functioning of the body 
(CDC, 2019). There are three types of HF, left-sided HF, right-sided heart failure, and 
congestive HF (which is often referred to as just heart failure) (“Types of Heart Failure, 
n.d). There are two types of left-sided HF, systolic and diastolic HF. Right sided HF is 
generally a consequence to left-sided HF, which results in fluid and pressure build-up, 
leading to damage of the right ventricle. When the right ventricle is unable to pump 
adequately, it leads to blood building up in the veins, and thus swelling occurs. 
Congestive HF (CHF) occurs when blood flow is decreased, which results in slow return 
of blood back to the heart; this leads to congestion in the tissues, and fluid build-up in the 
lungs, resulting on shortness of breath (SOB) and edema (“Types of Heart Failure, n.d). 
 As HF cannot be diagnosed by labs values alone, a physician must acquire a 
physical examination, past medical history, chest radiography, blood labs, signs, 
symptoms, and especially, an echocardiogram (King et al., 2012). The signs and 
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symptoms of HF can include stomach, foot, leg, or ankle edema, along with weight gain. 
Individuals with HF may also experience difficulty breathing while performing every-day 
tasks or if lying down (CDC, 2019). When classifying HF, the New York Heart 
Association Functional Classification is generally used to classify an individual’s 
symptoms. There are four classes of patient symptoms and four classes of objective 
assessment, as displayed in Table 1. Therefore, the HF classification is based on 
symptoms that the patient experiences, and “objective evidence” observed by the 
practitioner (“Classes of Heart Failure”, n.d) 
 
TABLE 1: New York Heart Association Functional Classification  
Class Symptoms 
I Physical activity is not limited, and does not result in fatigue, dyspnea, or 
palpitation.  
II Physical activity is slightly limited, but the individual is comfortable when 
resting. Regular physical activity results in fatigue 
III Physical activity is limited, but resting is comfortable.  
IV Inability to participate in physical activity, without feeling discomfort. At 
rest, HF symptoms are present.  
Class Objective Assessment  
A CVD objective evidence is not present. The individual has no symptoms 
or physical activity limitations 
 
B CVD evidence is limited. Individual experiences symptoms which are 
mild and slightly decrease exercise ability  
C Objective assessment shows moderately severe evidence of CVD. Physical 
activity is decreased due to symptoms. 
D CVD evidence is severe, and the individual experiences excessive 
limitations, even when resting.  
Note: Reprinted from “Classes of Heart Failure,” https://www.heart.org/en/health-topics/heart-failure/what-





Ejection Fraction/Systolic & Diastolic Function. 
 The main force behind the heart’s pumping action, is the left ventricle. The 
heart’s level of function can be evaluated by its ejection fraction (EF) percentage 
(“Understanding Heart Failure,” n.d).  Ejection fraction is a ratio, comparing the heart’s 
stroke volume to its end-diastolic volume, which depicts how well the left ventricle is 
emptying (Fukuta & Little, 2009).  In a 2013 article, Komaura discusses support for the 
hypothesis that HF is a “single syndrome” and that diastolic HF and systolic HF are two 
“phenotypes” at each end of a spectrum (Komaura, 2013). HF with preserved ejection 
fraction (HFpEF) is considered diastolic HF, and HF with reduced ejection fraction 
(HFrEF) is considered systolic HF (Komaura, 2013). In the case of systolic HF, 
inadequate amounts of oxygenated blood is delivered to the body, as the heart lacks 
sufficient pumping strength (Cleveland clinic). In the case of diastolic HF, the heart is 
able to pump and contract with the right amount of strength, but both ventricles are 
inflexible, dense (“Understanding Heart Failure,” n.d) and unable to relax (King et al., 
2012). This results in inadequate amounts of blood filling the ventricle, and a lack of 
“end-diastolic pressure,” (King et al., 2012) which leads to a lack of blood being 
delivered to the body (“Understanding Heart Failure,” n.d).   
Causes/Risk factors for Heart Failure 
 The results of diastolic and systolic HF occur when the heart has to compensate in 
response to stressors. The heart adapts to the stress when the angiotensin-aldosterone 
system and the sympathetic nervous system are recruited, which initiate an increase in: 
blood volume, blood pressure, stroke volume, as well as cardiac output. (King et al., 
2012). The stressors can include a number of underlying causes, many of which are 
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impacted by dietary choices. Underlying causes that put stress on the heart include 
coronary artery disease (CAD), high blood pressure (HTN), diabetes mellitus (DM), 
valvular heart disease, lack of physical activity, smoking, as well as obesity (King et al., 
2012).  
Coronary Artery Disease 
 Coronary artery disease is the contributing factor to more than half of people 
diagnosed with systolic HF (King et al., 2012). Coronary artery disease develops when 
the endothelial layer of the artery becomes damaged, resulting in lesions. Damage to the 
endothelial layer can be caused/agitated by excess lipids, cytokines, advanced glycation 
end products (AGEs) caused from uncontrolled diabetes, and from the release of 
hormones associated with vasoconstriction, in relation to HTN. Plaque develops when the 
adhesions fill with leukocytes (Libby & Theroux, 2005), cholesterol, calcium, fat, and 
other molecules (“Atherosclerosis,” n.d). As the plaque builds up, it results in the artery 
becoming narrower, which decreases the radius in which blood is able to flow through 
and thus, less blood flow to the body’s organs (“Atherosclerosis,” n.d). 
Hypertension    
 One of the biggest risk factors for cardiovascular complications and HF is HTN. 
In The Framingham Heart Study, “Lifetime Risk for Developing Congestive Heart 
Failure,”—which followed 3,757 women and 4,472 men— Lloyd-Jones et al. reported 
that for women, HTN can be attributed to 59% of congestive HF (CHF) risk, and for 
men, the number is 39% (Lloyd-Jones et al., 2002). High blood pressure puts an 
individual at risk because it can cause damage to the blood vessels, the arteries and to the 
heart (“High Blood Pressure,” n.d). When the heart is exposed to too much pressure or 
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volume for a long period of time, it changes and damages the heart, leading to the 
development of HF (Messerli,et al., 2017).The “overload” of pressure results in an 
increase in size of the left ventricle, as that is the compensatory mechanism used to 
accommodate the higher pressure of blood. This results in worsened diastolic function, 
and thus leads to diastolic HF (HFpEF) (Messerli et al., 2017). Consequently, when blood 
volume has exceeded its normal level, the left ventricle has to stretch further, resulting in 
left ventricle deterioration, therefore, leading to systolic HF (HFrEF) (Messerli et al., 
2017). HTN is diagnosed when systolic blood pressure is ≥ 140mm Hg or when diastolic 
blood pressure is 80-89 at two different doctor’s visits (“High Blood Pressure,” n.d). 
There are two types of HTN, primary HTN and secondary HTN.  Primary HTN 
progresses over an extended period of time, such as part of the aging process, and 
secondary HTN can be a result of certain medication or a consequence following another 
medical diagnosis (“High Blood Pressure,” n.d). HTN can be classified into 4 different 
stages, as displayed in Table 2 (New acc/aha, 2017).  
Table 2: Stages of HTN 
Blood Pressure Reading  
Normal  ≤ 120/80 mm Hg 
Elevated 120-129/≤80 mm Hg 
Stage 1 130-139/80-89 mm Hg 
Stage 2 ≥140/ ≥ 90 mm Hg 
Hypertensive Crisis > 180/ >120 mm Hg 
Note: reprinted from New ACC/AHA High Blood Pressure Guidelines Lower Definition of Hypertension 
https://www.acc.org/latest-in-cardiology/articles/2017/11/08/11/47/mon-5pm-bp-guideline-aha-2017, 2020 




Table 3 displays the 4 stages of damage or dysfunction that the heart can endure resulting 
from high blood pressure (Messerli et al., 2017).  
Table 3: Stages of Heart Dysfunction  
Stage 1 Impairment of the left ventricle functioning, but no presence of heart 
enlargement  
Stage 2 The left ventricle becomes enlarged, in addition to impairment of left 
ventricle functioning. 
Stage 3 Occurs when the person is diagnosed with diastolic HF (HFpEF). 
Stage 4 Occurs when there is unusual enlargement of the left ventricle along with 
systolic dysfunction (HFrEF) 
Note: reprinted from The Transition From Hypertension to Heart Failure: Contemporary Update By 
Messerli et al 2017 By Elsevier  
https://www.sciencedirect.com/science/article/pii/S2213177917303177?via%3Dihub 
 
While there are some non-controllable risk factors, such as family history, age, sex, race 
and genetics, HTN can often be prevented, or nonetheless partially controlled through 
lifestyle changes. Lifestyle changes include following a diet rich in fruits and vegetables, 
participating in regular exercise, smoking cessation, and weight control (“High Blood 
Pressure,” n.d). Medication may also be used to relieve some of the volume overload, and 
thus reduce pressure. 
Diabetes  
 Another underlying factor that can contribute to the development of HF is 
uncontrolled diabetes (DM). There are several types of diabetes, the main two being type 
1 and type 2 diabetes. Type 1 DM makes up about 10% of the cases and usually develops 
early on in life. Type 1 DM is an autoimmune disease where the pancreas stops 
producing insulin as a result of β-cells destruction (Palicka, 2002). Type 2 DM makes up 
the other 90% of DM cases, and is characterized by insulin resistance, which can arise as 
a consequence of certain lifestyle choices and other factors (Palicka, 2002). When the 
body is not able to produce insulin, or adequate amounts of insulin, the body does not 
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recognize that there is glucose available to use; this results in excess glucose in the blood 
(hyperglycemia). In the article “Diabetes and Advanced Glycation End Products,” 
Vlassara and Palace discuss the negative consequences that long term hyperglycemia can 
have, and how it can lead to the development of heart disease. When DM is uncontrolled 
and hyperglycemia is present over an extended period of time, it leads to the development 
of advanced glycosylated end products (AGEs), which are believed to be a principal 
factor in the progression of complications associated with diabetes (Vlassara & Palace, 
2002). When glucose concentrations are high in the blood, there is an increased risk that 
molecules, such as lipids and protein, will bond with the glucose (glycosylation). When 
those molecules become glycosylated, it can interfere with how the body recognizes and 
manages those molecules (Vlassara & Palace, 2002). One example of this is when 
apoprotein B (ApoB) is glycosylated. In the article “Glycosylation End Products 
Blocking Uptake by the Low Density Lipoprotein Receptor,” Bucala et al. (1995) found 
that when apoB is glycosylated, its functioning becomes modified, and the “ability of 
LDL to undergo receptor-mediated uptake and degradation” is altered. As the disposal of 
LDL becomes reduced, and the amount of LDL circulating in the blood is elevated, it 
puts the individual at risk for atherosclerosis (CAD), as excess lipids can contribute to the 
development and progression of plaque build-up, and thus a narrowing of the artery 
(Bucala et al., 1995).  
Treatment of Heart Failure 
 Treatment of HF includes a combination of both medical approaches and lifestyle 
changes. As HF is a chronic condition, the goals of therapy are to help the patient manage 
his or her symptoms, which generally stem from underlying medical diagnoses such as 
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diabetes, CAD, and high blood pressure, which all cause the heart to work harder 
(“Treatment Options For Heart Failure,” n.d). Management for HF includes the use of 
medications, along with a set of dietary and lifestyle recommendations, which can vary 
depending on underlying medical diagnoses, class of HF the patient is diagnosed with, 
and the clinical signs and symptoms present (Yancy et.al., 2013). For example, Yancy et 
al. state that sodium recommendations for different stages of HF may differ, and that 
while heavily restricted sodium for some stages of HF may be beneficial, there is limited 
research as to how much of a sodium restriction is beneficial for other stages of HF 
(Yancy, et.al, 2013).  While in patients with a diagnosis of diabetes, the goal is to control 
blood glucose levels and prevent hyperglycemia, which includes its own medication and 
dietary protocol (Yancy et al, 2013).   
 Some of the most common medications used for managing HF include diuretics,  
(CDC, 2019) ace inhibitors, aldosterone antagonists, angiotensin receptor blockers, beta 
blockers, digoxin, and isosorbide dinitrate/hydralazine hydrochloride (“Heart Failure,” 
n.d). Diuretics help the body eliminate excess build-up of fluid in the body. Ace 
inhibitors are utilized to help decrease high blood pressure, which causes the heart to 
work harder. Aldosterone antagonists help the body to get rid of extra sodium, which can 
be passed through the urine. (“Heart Failure,” n.d).).As the blood’s volume lessens, so 
does the amount of work the heart has to do to, in order to pump blood through the body. 
Angiotensin receptor blockers reduce blood pressure by helping blood vessels to relax. 
Beta blockers also help reduce blood pressure, by decreasing the rate at which the heart 
beats. Digoxin is used to strengthen the heart’s beat, allowing it to pump a larger amount 
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of blood throughout the body. Isosorbide dinitrate/hydralazine hydrochloride helps blood 
vessels to relax, decreasing the heart’s work (“Heart Failure,” n.d). 
 If patients still experience difficulty with managing their HF symptoms, 
additional medical treatment options include a pacemaker or an implantable cardioverter 
defibrillator (ICD). A biventricular pace maker is used to help both sides of the heart 
pump at the same time and an implantable cardioverter defibrillator (ICD) is used when 
the heart beats are fast and irregular, which if not treated, can result in cardiac arrest 
(“Heart Failure,” n.d).If those treatment options do not work, a mechanical heart pump 
may be utilized, which aids the heart with its task of pumping blood throughout the body. 
If all interventions do not suffice, a heart transplant may be a final mode of treatment 
(“Heart Failure,” n.d). 
 Lifestyle recommendations for HF often include incorporating physical activity, 
depending on what the patient can handle, (CDC, 2019), and adhering to the AHA dietary 
recommendations. The AHA recommends limiting dietary sodium intake 1,500-
2,300mg/day, limiting saturated fat, alcohol consumption, and sugar, and increasing fruit 
and vegetable consumption for increased fiber intake (CDC, 2019), (The American Heart 
Association Diet and Lifestyle Recommendations, n.d). As lifestyle changes can be 
overwhelming and difficult to adhere to, meeting with a Registered Dietitian (RD), or 
participating in a support group or a shared medical appointment (SMA) can be helpful 
and encouraging when making those changes (Heart disease-CDC). In fact, many studies 
have reported that number of hospitalizations rise when HF patients do not have adequate 
support from others (Yancy et.al., 2013). Therefore, group appointments such as SMAs 
can be a practical for patients with HF.  
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Impacts of Diet 
 While the physiological impacts of certain medical diagnoses, such as CAD, HTN 
and diabetes, can induce inflammation, putting stress on the heart, one significant risk 
factor that cannot be overlooked is the association between dietary habits and HF. There 
are different perspectives as to how diet can impact the heart’s function. Research has 
been done to determine the impacts of consuming specific food groups, such as meat, 
fruits and vegetables, as well as the impacts of consuming specific macro or 
micronutrients such as fat, cholesterol and sodium. Some research has also observed the 
effects of when a specific diet regimen is followed, such as a vegetarian, Mediterranean, 
or the DASH diet and past literature show trends that a diet, high in fat, cholesterol, and 
sodium, and low in fruits and vegetables, can increase an individual’s risk for HD and 
HF, and can negatively impact the outcomes of those already diagnosed with HD and HF. 
Nutrition related research regarding HF outcomes has examined the effects of single 
nutrients, such as saturated fat and sodium intake, as well as dietary regimens such as the 
DASH and Mediterranean diets. While the research may be inconsistent, and highly 
debated, the AHA dietary guidelines remain as such: eat a diet that includes a variety of 
fruits and vegetables, whole grains, low-fat dairy products, lean meat, nuts and legumes, 
non-tropical vegetable oils, and limit the amount of trans fat, saturated fat, red meat, 
sweets, and sodium (AHA). While some components of the recommendations are still 
debated (saturated fat, red meat, and sodium intake), currently enough quality evidence 
exists to influence the recommendations. Therefore, when providing extensive nutrition 
education to HF patients, an educator must be knowledgeable regarding the literature that 
has influenced the current recommendations.  
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Saturated Fat & Cholesterol   
 The correlation of saturated fat and heart disease dates back as early as 1957, 
when Keys et. al reported a positive influence of saturated fat intake on cholesterol levels 
and the risks and outcomes of heart disease (Dietschy, 1998). As research has progressed, 
high dietary intake of saturated fats has continued to show negative health consequences 
regarding heart disease and HF outcomes. For the last 25 years, epidemiologic studies 
have indicated that dietary fat intake has a positive correlation with cholesterol and 
coronary heart disease (CHD) mortality (Dietschy, 1998). The 2015-2020 Dietary 
Guidelines recommend to limit saturated fat to <10% of total calories (“A Closer Look 
Inside, n.d), and the American Heart Association recommends that saturated fat should 
only make up only 5-6% of total daily calories (“The American Heart, n.d). However, 
despite the recommendations that saturated fat intake should be limited, and the body of 
evidence that supports it, there is still conflicting research, making the impacts of 
saturated fat on heart disease a controversial issue. For example, Ascherio et al. discuss 
the relationship between coronary heart disease incidence and dietary fat & saturated fat 
intake. After observing the effects, it is reported that a diet high in cholesterol and 
saturated fat is linked to coronary disease and increases that risk. However, they also state 
that those effects may be partially explained by a diet that is also low in fiber. The 
findings conclude that although the positive benefits of decreasing saturated fat and 
cholesterol intake decreases heart disease risk, it may not have quite as big of an impact 
as when those changes are followed by increasing the consumption of fiber rich foods. 
Ascherio et al. emphasize that prevention for coronary disease should consist of a variety 
of dietary components, including decreasing saturated/trans fats, decreasing cholesterol, 
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as well as increasing foods that are high in fiber, such as fruits and vegetables (Ascherio 
et al., 1996).  
 In the article “The Role of Lipids and Lipoproteins in Atherosclerosis,” Linton et 
al. (2019) discussed how cholesterol contributes to plaque build-up in the arteries and 
how it can be directly related to atherosclerosis (CAD) development. When there are high 
levels of LDL-cholesterol (LDL-C), as well as the main LDL protein, apolipoprotein B 
(apoB) 100, it increases the risk of cardiovascular problems that are related to 
atherosclerosis. For example, lipoproteins that contain apoB can penetrate and reside 
inside the wall of the artery, and can initiate the “inflammatory response that promotes 
the development of atherosclerosis” (Linton et al., 2019). When high levels of 
inflammation are not resolved, it can lead to the build-up of plaque (Linton et al., 2019). 
As LDL-C is a major impactor for the development of CAD, and CAD is a critical 
underlying risk factor for HD and HF, it is important that health professionals remind 
these patients of the importance of monitoring LDL-C concentrations in the body. 
However, the overall effect of total cholesterol (TC) concentrations and the impact on 
HD & HF continues to be controversial. 
 As some studies have reported that low cholesterol levels may result in worse 
CHF outcomes, and greater risk of mortality, this has been an area for research (Sakatani 
et al, 2005). Sakatani et al. investigated the effects of cholesterol levels on CHF patients. 
They divided the patients into 2 groups; one group included the patients diagnosed with 
CAD, and the other group included those without a CAD diagnosis (Sakatani etval., 
2005). In this study, they reported that total cholesterol (TC) concentrations were not 
significantly different between those who survived and those who didn’t survive at the 
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time of follow up, when considering the patients in both groups. However, when each 
group was analyzed separately, they found some differences. For example, in the CAD 
group of patients, LDL and TC were lower in those who survived vs those who didn’t 
(Sakatani et al., 2005).  As for the patients without CAD, they reported that when TC was 
low, it was linked to a poorer outcome. They concluded, that while TC is important for 
forecasting CHF outcomes, patients with a diagnosis of CAD should be assessed 
differently than if CAD is not an underlying risk factor (Sakatani et al., 2005). In addition 
to the fact that underlying diseases, such as CAD, can impact cholesterol and fat 
recommendations for patients, some studies have looked at how types of LDL cholesterol 
may impact outcomes.  
 In the article, “The Evidence for Saturated Fat and for Sugar Related to Coronary 
Heart Disease,” DiNicolantonio, Lucan, and O’Keefe (2015) discuss how the size of LDL 
cholesterol particles, such as small dense ones as opposed to ones that are larger and 
more buoyant, may be something to consider with regards to CHD outcomes 
(DiNicolantonio et al., 2015). They state that LDL that is smaller and denser is more 
vulnerable when it comes to oxidation, and that those types of particles are more likely to 
produce inflammation than more buoyant/large LDL (DiNicolantonio et al., 2015). In 
addition, St-Pierre et al. found, that LDL that was smaller and denser indicated an 
increased Ischemic Heart Disease (IHD) risk during a follow up, after a short period of 
time of about 7 years. They also noted that larger LDL particles were not indicative of an 
increased IHD risk in men (St-Pierre et al., 2004). As there has been some fascinating 
research illustrating the complexity to this issue, it is generally not knowledge that 
patients have the time and energy for. While some foods may produce cholesterol that is 
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denser or more buoyant, it is much simpler to just focus on reducing cholesterol 
containing foods.   
Sodium  
 In addition to saturated fat and cholesterol, sodium is a key nutrient of interest 
when it comes to HF lifestyle recommendations. Sodium is a necessary 
mineral/electrolyte for the body; it helps manage fluid balance, and aids in proper 
function of muscles and nerves (Lewis, 2018). However, when too much sodium is 
consumed in the diet, it can lead to increased blood volume, which makes it harder for the 
kidneys to filter. When the kidneys are challenged to filter excess blood, it can decrease 
their ability to eliminate toxins and excess fluid that resides inside of cells, and the excess 
blood volume then puts pressure on the heart (“How salt can impact your blood pressure, 
heart and kidneys,” 2017). While the AHA recommendations still hold that sodium 
should be restricted to 1,500-2,300mg per day (The American Heart Association Diet and 
Lifestyle Recommendations, n.d) there continues to be conflicting evidence as to how 
large an impact sodium consumption has on cardiovascular outcomes. It has been noted 
that some of the controversial results regarding sodium’s impact on the development of 
high blood pressure may be due to the fact that some people are considered “salt-
sensitive” and others “salt –resistant” (Morris et al., 2016).While some studies have 
found that there is no significant association regarding negative cardiovascular outcomes 
and sodium intake, there is enough compelling evidence that has influenced the 
recommendations to remain as they are. Reduced sodium consumption continues to be a 
major controllable risk factor for the development of HTN and to prevent poorer 
cardiovascular outcomes. According to the World Health Organization (WHO), about 
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13% of deaths around the world are a result of HTN, which is strongly impacted by 
sodium intake (“Global Health Risks, 2009). Therefore, as HTN is considered a major 
risk factor for HF & negative outcomes, it is important to understand the research that has 
influenced sodium recommendations.  
 In 2013, Aburto et.al performed a meta-analysis using “36 randomized controlled 
trials,” and concluded that systolic and diastolic blood pressure is significantly decreased 
when dietary sodium intake is reduced (Aburto et al., 2013). They found that systolic 
blood pressure was reduced by 3.39mmHg, and diastolic blood pressure was reduced by 
1.54mmHg (Aburto et al., 2013). The results of this study mirrored those from previous 
systematic reviews, which also have concluded that lower sodium consumption decreases 
blood pressure in both individuals with and without HTN. In one of the first prospective 
studies, He, et.al discovered a “strong and independent relationship between dietary 
intake of sodium and increased risk of CHF in overweight persons” (He et al, 2002). This 
study included 5,233 non-overweight individuals and 5,129 overweight individuals. After 
a 5-10 year follow up, the researchers found that as quartile of sodium intake went up, so 
did the risk of CHF, but the percent of risk for each quartile was higher in the overweight 
group. They concluded that sodium intake in overweight individuals was significantly 
associated with CHF risk, but not in non-overweight individuals (He et al., 2002). In 
addition to leading to negative CHF and CVD health outcomes, studies have also 
reported that higher sodium intake can lead to higher risks of stroke and stroke mortality. 
In 2018 a meta-analysis of 16 prospective cohort studies was conducted and the 
researchers reported the outcomes of sodium consumption and CVD outcomes (Zhu et 
al., 2018).  The individuals in the study were followed up between 3.5 and 19 years. After 
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the follow up, researchers found that the results regarding sodium intake and CVD 
outcomes are mixed. They also saw a trend: increased sodium intake is associated with an 
increased risk of stroke and stroke mortality. As with the previous studies, Zhu et al. also 
reported that there was a trend regarding high sodium intake and CVD, but that this was 
only observed in the overweight individuals, not the non-overweight individuals (Zhu et 
al., 2018).  It is evident that there is still controversy regarding this topic. But, as there is 
a continued strong association between high sodium intake and negative health outcomes, 
the recommendations have not changed and healthcare professionals continue to 
encourage reducing dietary sodium intake. 
  The effects of single nutrients such as saturated fat, cholesterol, and sodium can 
contribute to adverse cardiovascular health outcomes, but those effects are not so black 
and white. Managing cardiovascular health, and overall health depends on more than 
single nutrients or single lifestyle habits. The AHA recommendations for managing HF 
include a variety of dietary changes for a reason, and many studies, such as one done by 
Mente et al., suggest that the total dietary composition should be focused on, not just 
single foods or nutrients (Mente et al., 2009). Therefore, many different types of dietary 
regimens have been studied, such as vegetarian type diets, Mediterranean diets, and the 
DASH diet. 
DASH diet  
 The DASH diet began in the 1990’s, with an objective to determine how diet 
impacts the outcome of HTN (Challa et al., 2019). The DASH diet was inspired by 
studies that discovered an association between vegetarian type diets and a reduction in 
blood pressure (Kerley, 2018). Following the DASH diet includes reducing the 
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consumption of animal proteins, sugar, fat and highly processed foods. The diet 
emphasizes consumption of wholegrain carbohydrates, a variety of fruits and vegetables, 
nuts, seeds, as well as fish and lower fat dairy products (Kerley, 2018). The diet 
recommends 5 servings of vegetables, 5 servings of fruit, 7 servings of carbohydrates, 2 
servings of low-fat dairy products, ≤ 2 servings of lean meat daily, and incorporating 
seeds and nuts 2-3 times throughout the week (Challa et al., 2019). In one of the earlier 
studies, “A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure,” Appel et 
al. studied 459 adults that were assigned to one of three diet groups. The groups consisted 
of a control diet, a diet with increased amounts of vegetables and fruits, and a 
“combination diet” which was low in fat and saturated fat, contained low- fat dairy 
products, and incorporated lots of vegetables and fruits. All participants began the study 
consuming a control diet for a 3 week period, and then had blood pressure measurements 
taken. Then, the participants were appointed to one of the three diets, and continued with 
that diet assignment for a total of 8 weeks, with periodic blood pressure (BP) 
measurements taken. The amount of sodium for each diet was around 3,000mg/day. After 
study completion, the researchers found that the group with increased fruits and 
vegetables had BP reductions of -2.8mmHg for systolic and -1.1mmHg for diastolic BP. 
The combination diet showed the greatest improvements, of -5.5mmHg and -3.0mmHg 
for systolic & diastolic BP, when compared to the control group. It is also noted that the 
participants in this study, whom were diagnosed with HTN, had comparable reductions in 
blood pressure to other trials using “drug monotherapy” to treat HTN (Appel et al., 
1997). In another study, researchers reported results that linked adherence to the DASH 
diet to a reduction in HF incidence (Levitan et al., 2009). The study looked at 36,019 
23 
 
women from ages 48-83, who had no history of heart disease or diabetes. The participants 
filled out food diaries, which were then scored based on how each food item compared to 
the DASH diet, and how close the person’s intake was to 2 specified food/nutrient 
guidelines. The participants with higher scores had diets that were more similar to the 
DASH diet than the participants who had lower scores. After confounding factors were 
controlled for, the researchers found that the individuals whose diets were closer to the 
DASH recommendations had a “37% lower incidence of HF,” in comparison to 
participants who had lower scores (Levitan et al., 2009).  
Heart Failure and Shared Medical Appointments (SMAs) 
 When considering the numerous potential medical diagnoses, and various lifestyle 
habits that can lead to the development or worsening of HF, it is no wonder this issue has 
continued to grow. The AHA dietary recommendations for managing HF are extensive. 
The recommendations include variety because the literature has indicated that the 
management of this disease does not solely depend on a few specific food choices or 
avoidances, but that the best outcomes arise when individuals include a variety of 
changes. As uncontrolled HTN, DM, and CAD, can all contribute to HF, and all have 
recommended dietary and lifestyle recommendations, it is understandable how 
individuals can have difficulty with dietary adherence. Not to mention, many of these 
patients have more than one underlying disease risk, and often take multiple medications. 
Therefore, due to the complexity of this disease, one method that is increasing popularity 





What are SMAs? 
 The concept of group visits was created in Northern California at Kaiser, in 1996, 
by a doctor named Edward Noffsigneer, PhD, who started what was known as “the drop-
in group medical appointment model” (Stein, 2011). As time has progressed, increasingly 
more medical organizations have implemented group visits for patients, as it can help to 
not only reduce costs, but also increases productivity (Stein, 2011). The difference 
between SMAs and support groups, is that SMAs have a medical and educational 
component. An SMA can have a wide range of patients, anywhere between 5 patients to 
20 patients, and includes a combination of methods to help with patient success. (Stein, 
2011). The duration of SMAs is typically 1-2 hours, depending on what is being covered 
in the appointment (Edlemen et al., 2012). SMAs are run by a multi-disciplinary medical 
team (Shared medical appointments, n.d), and are generally considered for the 
management of chronic conditions, such as DM, HTN, asthma, and cardiovascular 
diseases, such as HF (Shared Medical Appointments, n.d). The multi-disciplinary team 
can consist of all or some of the following healthcare professionals: a doctor, a nurse, a 
pharmacist, a dietitian (Shared medical appointments, n.d) and sometimes a social worker 
(Smith et al., 2014)  
 While SMAs have been around since 1990s, the research is still limited and 
controversial. In 2012 it was stated that there is not “enough evidence to make a strictly 
evidence-driven decision about implementation of SMAs in any context except diabetes,” 
(Edlemen et al., 2012). That trend continued in 2017 articles, as authors’ commented that 
the published literature for HF SMA outcomes remains limited (Cohen et al., 2017). In 
the article, “A Heart Failure Management Program Using Shared Medical 
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Appointments,” the hypothesis was not supported, and patients who were in the HF SMA 
group did “not have lower 12-month hospitalization or mortality rates, shorter hospital 
stays, or longer time to hospitalization compared to the HF clinic only” group (Carrol et 
al., 2017). However, the current literature that exists can provide a platform for future 
research, such as gaps to be addressed, and the types of outcomes to be assessed. As the 
prevalence of HF continues to dramatically rise, and studies have reported that about 70% 
of the readmissions related to HF could have been be prevented if self-management skills 
in patients were improved, it is pertinent to research the benefits of SMAs regarding 
outcomes of this disease (Smith et al., 2016).  
 The use of SMAs regarding the management of HF has started to gain some 
traction, and there are a few studies that have shown promise and can help direct the 
future research. For example, some of the current research regarding HF SMAs has 
looked at how attendance to SMAs affects hospitalization rates, self-care skills, HF 
related discouragement, quality of life (QOL) (Smith et al., 2015) as well as mortality, 
(Carroll et al., 2017). Two key articles regarding SMAs include the 2014 & 2015 articles 
by Smith, et al. In the 2014 study, 2 groups were compared, one received standard care 
(n=106), and the other group participated in SMAs (n=92). They reported that vasodilator 
and beta blocker adherence was poorer in the standard care group versus the SMA group, 
and that the SMAs were well accepted by the patients (Smith et al., 2014). In 2015, the 
researchers looked back at the previous study and this time focused on the methods, 
materials, and outcomes. They found that the patients who were in the SMA group used 
checklists and calendars to manage daily weights, to a higher degree than the patients in 
the standard care group. They also reported that the SMA group had greater 
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improvements for HF self-care skills, decreasing salt intake, taking medications, 
incorporating exercise, and had less hospitalizations than the standard care group (Smith 
et al., 2015). In another article, researchers observed how dietitian consultation effected 
the reduction of cardiovascular disease risk factors in individuals who were considered 
“high risk” (Ross, et.al, 2019). They found that for HDL, lipid levels, triglycerides, LDL, 
and total cholesterol, dietetic consultation was “at least as effective as usual minimal 
care,” and that that 4 studies indicated a “superior effect” with the use of a dietitian. 
(Ross et al., 2019).  
 While there is some positive research showing improvements in HF patients who 
participate in SMAs (Ross, et.al, 2019), (Smith et al., 2014), (Smith et al., 2015), there is 
also controversy (Carrol et al., 2017), which is why it is important that more research is 
conducted. The current, limited literature has reported on some of the impacts that SMAs 
have on patient outcomes, such as medication adherence, dietary adherence, laboratory 
values, as well as compared control groups to intervention groups over short and long 
periods of time. Some of the research has included the addition of an RD to the 
interdisciplinary team. However, the impact that RD provided nutrition education has on 
HF related outcomes is limited. As dietary composition is a major factor for underlying 
risk factors (cholesterol, HTN, type 2 diabetes, CAD) to HF, it is essential that more 
research is conducted with the addition of an RD, and with a greater focus on nutrition 
education. 
 In conclusion, HF is a complex chronic condition. The management of HF 
requires a team of healthcare professionals and a delicate balance of managing underlying 
medical conditions, medications, and dietary management. As heart disease remains the 
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number one cause of death in the United States, it is evident that changes to patient care 
such as SMAs and a greater focus on dietary education are crucial. The gaps in the 
literature previously discussed along with the increasing prevalence of heart disease 
support the purpose of this pilot project: to collect and report descriptive statistics from 
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Abstract:  
 The purpose of this pilot project was to examine descriptive statistics from 7 
patients who participated in HF SMAs at a mid-sized heart center in the northwest, in which 
nutrition education was provided by an RD. Information collected included blood pressure 
(BP), heart rate (HR), weight, scores from the Minnesota Living with Heart Failure 
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(MLHF) Survey, and the Atlanta Heart Failure Knowledge (AHFK) questionnaire. Due to 
small sample size and lack of control group, simple descriptive statistics, such as mean and 
median were used to examine the data. Three of the participants were female and 4 were 
male. Five patients in this group had a diagnosis of HF with reduced ejection fraction 
(HFrEF), and two patients had a diagnosis of HF with preserved ejection fraction (HFpEF). 
Average weights of the participants ranged from 171.4 lbs to 339.6lbs. Quality of life 
(QOL) for this group of patients was diverse, average MLHF scores ranging from 0.4-78.3. 
The 3 lowest scores on the MLHF questionnaire and the 3 lowest average HRs were 
observed in the 3 patients (21, 22 & 32) who had the lowest recorded weights in the group 
(<200lbs). The 2 highest average BPs were observed in the 2 patients (20 & 25) with 
HFpEF. One limited potential trend that was detected within this data was that the 3 
patients with average weights <200lbs appeared to have lower MLHF scores (indicating 
higher QOL), as well as lower HRs, than the 4 patients with weights >200lbs. 
 
 
Introduction:                  
 Heart Failure (HF) contributes about $30.7 billion to healthcare costs annually, 
and impacts approximately 5.7 million Americans (Centers for Disease Control and 
Prevention [CDC], 2019). Risk factors that can contribute to the development of HF 
include: coronary artery disease (CAD), high blood pressure/hypertension (HTN), 
diabetes (DM), smoking, a high sodium, high cholesterol, and high saturated fat diet, lack 
of physical activity, as well as obesity (CDC, 2019).  
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 Treatment for HF includes a combination of medical and lifestyle approaches. 
Medications are used to help control underlying diseases, such as HTN, CAD, and DM, 
to decrease overall stress on the heart. Lifestyle changes such as increasing physical 
activity and changing dietary patterns are also recommended. The American Heart 
Association (AHA) emphasizes consumption of a variety of fruits & vegetables, low 
fat/fat free dairy, lean meats, as well as incorporating nuts and legumes, reducing added 
sugars, and limiting sodium consumption to 1,500-2,300mg/day.  
  In 2016, the AHA reported that, despite survival rates increasing, about half of 
those diagnosed with HF will not live past 5 years (Mozaffarian et al., 2016). Therefore, 
it is evident that additional interventions should be assessed regarding the maintenance of 
this disease. One proposed method is through shared medical appointments (SMAs). An 
SMA is typically a small group of approximately 10-15 patients, all with the same or 
related medical diagnosis/condition. These patients are seen by a multi-disciplinary 
medical team, consisting of a nurse, a doctor, a pharmacist, and sometimes a registered 
dietitian (RD). Together the patients share their experiences, concerns, questions, and 
discuss past stories with the SMA group (Shared Medical Appointments, n.d). SMAs are 
considered to be most beneficial for patients with chronic conditions, such as diabetes, 
HTN, asthma and heart disease/ HF (Shared Medical Appointments, n.d). In their 2015 
article, Smith et al found that a group of 92 patients involved in HF SMAs had a decrease 
of 33% in re-hospitalizations due to HF, compared to a control group who did not 
participate in an SMA (Smith, 2015). Current research has also observed the effects that 
SMAs have on other patient outcomes such as medication adherence, dietary adherence, 
and laboratory values. However, the impact that extensive RD provided nutrition 
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education has on HF related outcomes is limited. As the number of HF diagnoses 
continues to rise and dietary intake remains a major factor for underlying risk factors 
(cholesterol, HTN, type 2 diabetes, CAD) to HF, it is essential that more research is 
conducted with a greater focus on nutrition education. Therefore, the purpose of this pilot 
project is to examine descriptive statistics from patients who participated in HF SMAs, in 








This retrospective pilot study examined 7 HF patients that participated in a SMA at a 
mid-sized heart center in the northwest, between April 2018 and January 2020.  De-
identified data from the 7 HF patients was retrieved from an electronic health record 
database a mid-sized heart center in the northwest. Demographics for the SMA 
participants were collected, such as gender, age, and ethnicity. Inclusion criteria for this 
group included the following: >18 years old, heart failure diagnosis, patient attendance of 
≥ 3 visits, and enrolled in HF SMA program. This study was approved by Central 
Washington University’s Human Subject Review Board. 
Data Collection:  
Dependent Variables: 
Information collected from the de-identified patients included blood pressure (BP), heart 
rate (HR), weight, scores from the Minnesota Living with HF (MLHF) Survey, which 
was given at each visit, as well as the Atlanta Heart Failure Knowledge (AHFK) 
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questionnaire, which was given at 3 different times over the course of the study. For the 
purpose of this study, the MLHF and the AHFK questionnaires were utilized to determine 
if patient responses improved over time Patient attendance, HR, BP and weight were also 
observed  
Data Analysis: 
Due to small sample size and lack of control group, simple descriptive statistics, such as 
mean and median were used to examine the data. 
Results:    
 The results to this pilot project are mixed. Although there are not adequate 
amounts of data to draw any firm conclusions, the results do help generate some 
questions that could direct future research studies. Most of the data over the course of the 
SMAs fluctuated, and there were not many common trends among all patients. Some 
minor trends were present, including lower MLHF scores at the last visit compared to the 
first visit. However, even those trend lines fluctuated and did not show any clear patterns. 
This group of patients was diverse and ages ranged from 45-83 years old. Three of the 
participants were female and 4 were male. Five patients in this group had a diagnosis of 
HF with reduced ejection fraction (HFrEF), and two patients had a diagnosis of HF with 
preserved ejection fraction (HFpEF). 
Weights 
 When looking at the weights displayed on a line graph, 7 of the patients 
maintained their weight, with insignificant fluctuations throughout the course of the 
SMAs. See graph 1. Average weights of the participants ranged from 171.4 lbs to 
339.6lbs. The weights of 3 patients (20, 21, & 22), despite some fluctuations, were lower 
at the last appointment than the first appointment, indicating some potential weight loss 
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over time. The graph for patient 21, showed a slight downward trend in weight over time. 
Since most patients were on diuretic medications, weight changes were likely influenced 
in part, by those medications and/or associated changes to the regimen. Patients 24 & 32 
had good weight maintenance, with weight only fluctuating a total of 7lbs for patient 24 
and 5 pounds for patient 32. Patient 25 had the most significant weight change around 
visit 9, gaining about 47 lbs and then losing 52 lbs.  
MLHF/AHFK Questionnaires  
 At each visit, patients filled out the MLHF questionnaire, which measures quality 
of life (QOL) with HF. The scores range from 0 to 105. A score of, or near 0 indicates 
QOL is not significantly impacted by HF; and a score of, or around 105 indicates HF 
does impact QOL to a great degree. Results to the MLHF questionnaire show that the 
QOL for this group of patients was diverse, average scores ranging from 0.4-78.3. The 3 
lowest scores on the MLHF questionnaire were seen in the 3 patients with the lowest 
recorded weight averages (<200lbs). The highest scores were seen in the 4 patients with 
the highest average weights recorded (>200lbs). Patient 25 had the most significant 
weight change, but when observing the MLHF score at that visit, it did not seem to 
significantly increase in correspondence. However, patient 25 did have the highest 
MLHF average score of all the patients; the average score being 78.3 and the next highest 
average score only reaching 56.4.While all the scores fluctuated over the course of the 
SMA visits, the scores at the last visit for each patient was either the same, or lower than 
the first score. See graph 2.   
 The amount of data available for the AHFK questionnaire was not optimal, and 
therefore, it was difficult to draw any clear conclusions. The scores of the AHFK 
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questionnaire were not widespread, as the average score range was 22.7-26.3, being the 
number of questions answered correctly out of a possible 30 
Blood Pressure/HR 
 The average BPs for this group of patients ranged from normal to stage 2. The 2 
highest average BPs were observed in the 2 patients (20 & 25) with HFpEF. The rest of 
the patients were diagnosed with HFrEF. Other than the highest BPs being found in the 2 
patients with HFpEF, BP did not appear to be related to weight and there did not appear 
to be any consistencies with regards to average MLHF scores. 
 The 3 lowest average HRs were observed in the 3 patients (21, 22 & 32) who had 
the lowest recorded weights in the group (<200lbs). As previously stated, patients 21, 22 
& 32 also had the lowest average scores to the MLHF questionnaire. Therefore, this 
seems to be one of the limited potential trends that was detected within this data: the 3 
patients with average weights <200lbs appeared to have lower MLHF scores, as well as 
lower HRs, than the 4 patients with weights >200lbs.  
Discussion:  
 The purpose of this pilot project was to examine improvements in HF related 
outcomes in 7 patients who participated in HF SMAs over the course of 21 months. An 
RD was present for 12 months of visits, however, there was not adequate amounts of data 
to make any inferences regarding this as a unique variable. Despite the limited and 
inconclusive results to this pilot project, some potential trends were observed and could 
be elaborated on in future SMA studies. One potential relationship that could be 
expanded upon is between weight, HR and the scores to the MLHF questionnaire. Results 
from this project showed that the four participants whose weights were >200lbs had the 
35 
 
highest HRs and MLHF scores. However, this trend is reported with caution for several 
reasons; the correlation is inconsistent, as the patient with the highest average weight did 
not have the highest average MLHF score and furthermore, height/BMI was not factored 
into this observation. This observation therefore, warrants further research. If 
consistencies with this trend are present in future studies with better validity, it could help 
support the need for greater weight management education to be included in HF SMAs.  
See graph 3.  
 It was also observed that patients with weights >200lbs seemed to have a more 
volatile QOL, as indicated by the MLHF scores. Patients 25 (average weight 259lbs) and 
23 (average weight 253lbs) appeared to have the most variations in their MLHF scores. 
This observation may help support the fact that future SMAs should include weight 
management as a part of nutrition education. This observation of course, does not 
represent causality, but helps support why extensive nutrition education is crucial to the 
overall management of this disease. When considering an exacerbation of HF, a higher 
weight may lead to a more negative impact on QOL (high MLHF score).  Furthermore, 
while the MLHF scores fluctuated over the course of the SMA visits, the scores at the last 
visit for each patient was either the same, or lower than the first score, suggesting a 
trending improvement in QOL in some of the patients. For future studies looking at QOL 
of HF patients, an important factor to consider when interpreting the results is the time of 
year. Many individuals experience seasonal depression in the winter months, which could 
be a variable that could skew the data and cause variation that is not necessarily due to 
HF symptoms or attitude towards HF.  Due to the small sample size of this study, and the 
inconsistent attendances among the patients, this variable was not able to be extensively 
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explored. Although many patients seemed to have an upward spike in their MLHF score 
(lower QOL) at visit 8, this visit did not fall on the same month for each patient. The 
months included in visit 8 were June, May, November, February, and March. When 
looking at the patients with their 8th visit occurring in fall/winter months, their scores on 
the MLHF questionnaire were higher, than patients with their 8th visit falling in June and 
May. Although patient 22’s 8th visit fell in June, this patient did not have a MLHF score, 
so this patient was not included in this observation. Furthermore, patient 22’s 3 highest 
MLHF scores fell during the months of May, June, and October, and therefore, 
contradicts the potential correlation that MLHF scores will be higher in fall/winter 
months vs spring/summer months. Regarding BP and the MLHF questionnaire, no clear 
conclusions could be drawn, as most patients were likely on BP medications. For 
example, patient 25 had the highest average BPs, as well as the highest average MLHF 
score, but patient 20, with the second highest BP, had the second lowest score on the 
MLHF questionnaire. 
 Although the ability to make connections with this data is limited, it was observed 
that the 2 patients (20 &32) with the lowest average weights had the highest average 
AHFK scores. It cannot be concluded that a higher score is related to a lower body 
weight, however further studies could explore this potential connection. It is also 
interesting to note that patients 20 & 32 had the lowest recorded SMA attendance.  It’s 
plausible that these patients already had better control & knowledge regarding their HF, 
and thus did not need to attend as many visits as other patients.  Nonetheless, with the 
small study sample, no clear conclusions can be made with this data. 
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 Although the outcomes to this project unveiled more questions than answers, the 
variation among the data help illustrate the complexities of this disease and elicit more 
research regarding the effects of SMAs on HR, BP, weight, and QOL.  
Current Research/ Trends in SMAs 
 Although shared medical appointments have been around for a while, the 
evidence and support for them is still limited. In a 2012 systematic review, Eddlemen and 
colleagues stated that there was not an adequate amount of research available to 
implement SMAs for any diseases besides diabetes (Eddlemen et al 2012). Since then, 
research in HF SMAs has progressed, and some studies have even observed the impacts 
of nutrition education on HF related outcomes (Ross et al., 2019). A few trends on the 
literature are important to note, such as patients who participate in SMA’s are accepting 
of this method of health care delivery (Smith et al. 2014), and some research has reported 
that SMA patients have reductions in HF related hospitalizations compared to a control 
group (Smith et al. 2016). In a 2019 systematic review and meta-analysis, Ross et al 
reported outcomes between patients who participated in traditional medical care, which 
may or may not have included nutrition education, to patients who received a minimum 
of 1 face to face visit with an RD. Ross et al found that in some studies RD provided 
nutrition education was “at least as effective as usual minimal care,” and in others they 
reported a significant difference between the intervention and control group (Ross et al., 
2019).   
 The length of SMAs have ranged from 3 months (Ross et al, 2019) to 4 years 
(Delichatsios et al, 2015), and beyond, as well as the frequency of visits. There is a wide 
span of methods used, health care professionals included, and objective measures 
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observed. Regardless, there are still many gaps in the literature. For example, there is a 
limited amount of research observing the effects of consistent nutrition focused education 
for more than 12 months. Many studies have observed the results when an SMA group 
(including an RD) is compared to a control group (i.e a standard care group) but there are 
many uncontrolled variables in this flawed study design, as SMAs can differ widely from 
standard care. In the current literature, there was no research found that has compared 2 
SMA groups to one another with variables such as nutrition education content (extensive 
vs basic) and nutrition educator (a doctor, a nurse, a pharmacist, or an RD). Lastly, while 
some research has looked at laboratory tests, such as lipid panels (Ross, et.al, 2019), 
more research is needed to observe the effects that SMAs have on other measures, such 
as weight, HR, BP, as well as patient knowledge.  
 The results and questions that have been generated from this project could help 
guide future SMA research that includes measures of weight, HR, BP, and patient 
knowledge. By comparing 2 SMA groups to one another, this would help limit the 
amount of confounding variables present when comparing an SMA group to standard 
care.  In addition, this method could help isolate certain aspects of the SMAs, such as 
nutrition education and help answer some of the following research questions: How 
significant is the role of nutrition education with regards to HF related outcomes?  How 
extensive does nutrition education correlate with positive outcomes for weight, BP, HR 
and quality of life? How does patient knowledge, HR, BP and weight impact quality of 
life?  
Limitations 
 There are limitations regarding the results to this pilot project. Two main 
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limitations were the sample size and the lack of data from a control group. Although the 
data from the 7 patients spans 21 months, some patients missed visits, resulting in a fewer 
data points for those patients. While, the patients were exposed to RD provided nutrition 
education for 1 year, it was only once per month and inconsistent amongst the 
participants. Therefore, more frequent education sessions or follow-ups during the rest of 
the month may be warranted in future studies.  
Conclusions  
 
 Due to data limitations, no clear conclusions were identified. Some potential 
relationships were observed, such as between weight, HR and MLHF questionnaire 
scores, and therefore, one potential trend that was detected within this data was that the 3 
patients with average weights <200lbs appeared to have lower MLHF scores (indicating 
higher QOL), as well as lower HRs, than the 4 patients with weights >200lbs. As there 
were inconsistencies within the correlations of this data, the results should be observed 
with caution. Although the results generated more questions than answers, those 
questions may elicit more research regarding the relationship between HR, BP weight, 
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